Important Website to Check! FDA's Compounding Risk Alerts Page--webpage is intended to alert health care professionals of adverse event reports related to compounded drugs and furthering further FDA’s goal of protecting patients from unsafe, ineffective, and poor quality compounded drugs

The information provided on this webpage is intended to alert health care professionals of adverse event reports related to compounded drugs. Providing this information to health care professionals should further FDA’s goal of protecting patients from unsafe, ineffective, and poor quality compounded drugs.

Please contact compounding@fda.hhs.gov if you have any questions regarding the information provided in a compounding risk alert below:

• A Case of Hemorrhagic Occlusive Retinal Vasculitis (HORV) Following Intraocular Injections of a Compounded Triamcinolone, Moxifloxacin, and Vancomycin Formulation 
• FDA alerts health care professionals of adverse events associated with Guardian’s compounded triamcinolone and moxifloxacin product for intravitreal injection 
• FDA investigates two serious adverse events associated with ImprimisRx’s compounded curcumin emulsion product for injection

FDA encourages health care professionals to report adverse events and product quality defects associated with compounded drugs to FDA’s MedWatch Adverse Event Reporting program: 

• Complete and submit the report online at www.fda.gov/medwatch/report.htm; or
• Download and complete the form, then submit it via fax at 1-800-FDA-0178.

 quoted from here and continue to check the FDA's Compounding Risk Alerts for updates